Regulation of Platelet Function in Older Patients With Atrial Fibrillation
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Atrial Fibrillation, Thrombotic Risk. Basic parameters: from 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this observational study is to learn about the effects of antiplatelet drugs on patients over the age of 80 with atrial fibrillation. The main question it aims to answer is: -Is platelet reactivity effectively controlled in patients over the age of 80 diagnosed with atrial fibrillation following the Watchman procedure.
Detailed description
Cardiovascular disease remains the leading cause of death and the risk for morbidity and mortality due to cardiovascular disease is thought to increases with age. Platelets play a key role in cardiovascular disease as their activation is essential for the formation of an arterial thrombus, the precursor to myocardial infarction and stroke. Additionally, thrombosis has been shown to be linked to cardiac pathologies including atrial fibrillation. The link between optimal prevention of thrombosis and limiting the risk associated with increased bleeding has not been fully elucidated. Hence, our understanding of the prothrombotic state of the platelet and thrombotic risk in people over the age of 80 is not well understood. In this study, we evaluate the prothrombotic state of the platelets in patients in the cardiovascular clinic over the age of 80 diagnosed with atrial fibrillation who are taking antiplatelet medications to determine the benefits of these interventions in prevention of thrombotic events, propagation of the risk for atrial fibrillation, and bleeding
Primary outcome measures
- Platelet reactivity [Time frame: blood draw will occur prior to Watchman procedure and antiplatelet administration and 90 days following Watchman procedure while patients are taking antiplatelet drugs]
Eligibility criteria
Inclusion criteria
- diagnosed with atrial fibrillation, scheduled for a Watchman Procedure
Exclusion criteria
- Healthy, taking antiplatelet medication
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07724301 · HUM00295130